News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexigen Therapeutics, Inc. (OREX) IPO Raises $84 Million, Middle of Range



4/26/2007 11:06:45 AM

SAN DIEGO, April 26, 2007 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. announced today the initial public offering of 7,000,000 shares of common stock at a price of $12 per share. All shares are being offered by Orexigen. In addition, Orexigen has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any. Merrill Lynch & Co. acted as sole book-running manager and J.P. Morgan Securities Inc. acted as co-lead manager for the offering. JMP Securities LLC and Leerink Swann & Co., Inc. acted as co-managers for the offering. Orexigen's common stock will trade on the NASDAQ Global Market under the symbol "OREX."

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 25, 2007. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in a Phase III clinical trial, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial.

Contacts: Corporate Media Orexigen Therapeutics GendeLLindheim BioCom Partners Graham Cooper Stephen Gendel 858-436-8600 212-918-4650

CONTACT: Corporate: Graham Cooper for Orexigen Therapeutics,+1-858-436-8600; Media: Stephen Gendel of GendeLLindheim BioCom Partners,+1-212-918-4650

Ticker Symbol: (:OREX)

>>> Discuss This Story


Read at Reuters
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES